Get startedLog in
    Picture of Swedish Orphan Biovitrum AB (publ) logo

    SOBI — Swedish Orphan Biovitrum AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Biovitrum Says FDA Approves Gamifant® Treatment For Adults And Children With Macrophage Activation Syndrome In Still's Disease

    Picture of Swedish Orphan Biovitrum AB (publ) logoSwedish Orphan Biovitrum AB (publ)
    27/06/2025 23:56
    June 27 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST:

FDA APPROVES GAMIFANT® (EMAPALUMAB-LZSG) AS FIRST-EVER TREATMENT FOR ADULTS AND CHILDREN WITH MACROPHAGE ACTIVATION SYNDROME IN STILL'S DISEASE

Source text: ID:nWkr2kf430

Further company coverage: SOBIV.ST

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Swedish Orphan Biovitrum AB (publ)

    See all news